Section Arrow
CBIO.NASDAQ
- Crescent Biopharma Inc
Quotes are at least 15-min delayed:2026/01/01 06:13 EST
Regular Hours
Last
 11.86
+0.26 (+2.24%)
Day High 
11.9 
Prev. Close
11.6 
1-M High
16.3499 
Volume 
51.15K 
Bid
11.74
Ask
11.86
Day Low
11.4 
Open
11.75 
1-M Low
11.54 
Market Cap 
194.68M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 12.25 
20-SMA 12.96 
50-SMA 13.05 
52-W High 37 
52-W Low 9.81 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-46.00/-5.47
Enterprise Value
232.16M
Balance Sheet
Book Value Per Share
0.05
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MREOMereo BioPharma Group plc0.4167+0.0462+12.47%-- 
OTLKOutlook Therapeutics1.58-0.285-15.28%0.58PE
VNDAVanda Pharmaceuticals8.82+1.79+25.46%126.25PE
SLSSELLAS Life Sciences Group3.77+0.46+13.90%-- 
FBLGFibroBiologics0.2249-0.017-7.03%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improvedclinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.